These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25543684)

  • 1. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
    Aher RB; Roy K
    Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors.
    Tseng TS; Lee YC; Hsiao NW; Liu YR; Tsai KC
    Bioorg Med Chem Lett; 2016 Jan; 26(2):265-271. PubMed ID: 26707392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
    Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
    SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
    Hou X; Chen X; Zhang M; Yan A
    SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
    Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
    J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
    Kumari M; Chandra S; Tiwari N; Subbarao N
    BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
    Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
    J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
    Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
    Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of 3,4-Dihydro-2
    Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
    [No Abstract]   [Full Text] [Related]  

  • 11. Classification SAR modeling of diverse quinolone compounds for antimalarial potency against Plasmodium falciparum.
    Aher RB; Roy K
    Comb Chem High Throughput Screen; 2014; 17(5):396-406. PubMed ID: 24372050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
    Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
    J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the structural requirements in multiple chemical scaffolds for the selective inhibition of Plasmodium falciparum calcium-dependent protein kinase-1 (PfCDPK-1) by 3D-pharmacophore modelling, and docking studies.
    Aher RB; Roy K
    SAR QSAR Environ Res; 2017 May; 28(5):390-414. PubMed ID: 28562086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring structural requirements for a class of nucleoside inhibitors (PfdUTPase) as antimalarials: first report on QSAR, pharmacophore mapping and multiple docking studies.
    Ojha PK; Roy K
    Comb Chem High Throughput Screen; 2013 Nov; 16(9):739-57. PubMed ID: 23701009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicomplex-based pharmacophore modeling coupled with molecular dynamics simulations: An efficient strategy for the identification of novel inhibitors of PfDHODH.
    Manhas A; Lone MY; Jha PC
    J Mol Graph Model; 2017 Aug; 75():413-423. PubMed ID: 28651831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
    Ojha PK; Roy K
    Eur J Med Chem; 2010 Oct; 45(10):4645-56. PubMed ID: 20708304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.
    Xu M; Zhu J; Diao Y; Zhou H; Ren X; Sun D; Huang J; Han D; Zhao Z; Zhu L; Xu Y; Li H
    J Med Chem; 2013 Oct; 56(20):7911-24. PubMed ID: 24073986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
    Deng X; Kokkonda S; El Mazouni F; White J; Burrows JN; Kaminsky W; Charman SA; Matthews D; Rathod PK; Phillips MA
    J Med Chem; 2014 Jun; 57(12):5381-94. PubMed ID: 24801997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.